Superior Planning, LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History

Superior Planning, LLC’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$300	Buy	+5	New	+$315	﹤0.01%	1979

Other funds holding BMRN

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Superior Planning, LLC's BMRN Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in BioMarin Pharmaceuticals (BMRN) in Q3 2026: 5 shares worth $300. The stake represents ﹤0.01% of the portfolio and ranks #1979 among its holdings.

358 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

Superior Planning, LLC held 5 shares of BioMarin Pharmaceuticals worth $300 as of Q3 2026.
BioMarin Pharmaceuticals was a new Superior Planning, LLC position in Q3 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1979 holding.
358 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.